Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
pharmaphorum5d
AstraZeneca goes bigger in amyloidosis with Neurimmune deal
AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months.
Medscape1d
Sinusitis: A Practical Guide for Physicians
Dr. Tichenor is an allergist and internist in private practice in New York specializing in the treatment of sinusitis. He is an Instructor in Medicine at New York Medical College and is an ...
The Lancet6d
The amyloid clock: mapping Alzheimer's disease in Down syndrome
Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, CA 92121, USA ...